4.5 Article

Therapeutic approach with commercial supplements for pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels

Journal

ORPHANET JOURNAL OF RARE DISEASES
Volume 17, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13023-022-02465-9

Keywords

Pantothenate kinase; Pantothenate kinase-associated neurodegeneration; Coenzyme A; Acyl carrier protein; Pantothenate; Pantethine; Vitamin E; Omega 3; Carnitine; Thiamine

Funding

  1. Instituto de Salud Carlos III, Spain [FIS PI16/00786, PI19/00377]
  2. Fondo Europeo de Desarrollo Regional (FEDER-Union Europea), Proyectos de Investigacion de Excelencia de la Junta de Andalucia [CTS-5725, PY18-850]

Ask authors/readers for more resources

The study examined the therapeutic effectiveness of commercial supplements in mutant PANK2 cells, finding that these supplements were able to eliminate iron accumulation, increase expression levels of key enzymes, and improve pathological alterations.
Background Neurodegeneration with brain iron accumulation (NBIA) is a group of rare neurogenetic disorders frequently associated with iron accumulation in the basal nuclei of the brain characterized by progressive spasticity, dystonia, muscle rigidity, neuropsychiatric symptoms, and retinal degeneration or optic nerve atrophy. Pantothenate kinase-associated neurodegeneration (PKAN) is one of the most widespread NBIA subtypes. It is caused by mutations in the gene of pantothenate kinase 2 (PANK2) that result in dysfunction in PANK2 enzyme activity, with consequent deficiency of coenzyme A (CoA) biosynthesis, as well as low levels of essential metabolic intermediates such as 4 '-phosphopantetheine, a necessary cofactor for essential cytosolic and mitochondrial proteins. Methods In this manuscript, we examined the therapeutic effectiveness of pantothenate, panthetine, antioxidants (vitamin E and omega 3) and mitochondrial function boosting supplements (L-carnitine and thiamine) in mutant PANK2 cells with residual expression levels. Results Commercial supplements, pantothenate, pantethine, vitamin E, omega 3, carnitine and thiamine were able to eliminate iron accumulation, increase PANK2, mtACP, and NFS1 expression levels and improve pathological alterations in mutant cells with residual PANK2 expression levels. Conclusion Our results suggest that several commercial compounds are indeed able to significantly correct the mutant phenotype in cellular models of PKAN. These compounds alone or in combinations are of common use in clinical practice and may be useful for the treatment of PKAN patients with residual enzyme expression levels.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available